

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (OMB#xxxx-xxxx). Do not return the completed form to this address.

Category	# of PTC Reviewed	# of CRITICAL Deficiencies	# of Major Deficiencies	Briefly describe CRITICAL and/or Major Deficiencies
Informed Consent				
Eligibility				
Treatment				
Disease Outcome/Response				
Adverse Events				
General Data Management Quality				

Public Health Service
National Institutes of Health
National Cancer Institute
Bethesda, Maryland 20892

PRELIMINARY REPORT OF AUDIT FINDINGS

Revise Complete & Save

Credited Group: ECOG-ACRIN Auditing Group: ECOG-ACRIN Category: Treatment

Membership Study Type: Treatment Audit Type: Routine audit Components: REG P PTC

Audit Date: 10/13/2017 Date of Prior Audit: 07/11/2016 Audit Team Leader: [Redacted]

Institution CTEP Code / Name: CHRISTIANA Delaware/Christiana Care NCI Community Oncology Research Program, 200 Hygeia Drive, Suite 2400, Newark, Delaware-19713, USA

Institution CTEP Code / Name Tier1: CHRISTIANA Institution CTEP Code / Name Tier2: Delaware/Christiana Care NCI Community Oncology Research Program

CRITICAL AND/OR MAJOR DEFICIENCIES FOR REG: IRB, ICC and/or DTL YES NO Not Reviewed
If YES, briefly describe: [Redacted]

DRUG ACCOUNTABILITY /PHARMACY CRITICAL/NON-COMPLIANCE YES NO Not Reviewed
If YES or Not Reviewed, briefly describe: [Redacted]

PATIENT CASE REVIEW SUMMARY

UPLOAD THIS REPORT TO THE CLINICAL TRIALS MONITORING BRANCH (CTMB) AT NCI/CTEP INTO THE CTMB-AIS DATABASE WITHIN ONE WORKING DAY OF COMPLETING THE AUDIT .

Any data irregularities identified through quality control procedures or through the audit program that raise any suspicion of intentional misrepresentation of data must be immediately reported to CTMB. The CTMB must be notified immediately by telephone [(240) 276-6545] of any findings suspicious and/or suggestive of intentional misrepresentation of data and/or disregard for regulatory safeguards for any component (regulatory documentation, pharmacy and patient case review) of an audit. Similarly, any data irregularities identified through other quality control procedures suspicious and/ or suggestive of intentional misrepresentation of data must be immediately reported to CTMB. It is the responsibility of the Network Group or NCORP Research Base to immediately notify CTMB when they learn of any significant irregularities or allegations related to scientific misconduct by a staff member or institution participating in their research program. It should be emphasized that the irregularity/misrepresentation of data does not need to be proven, a reasonable level of suspicion suffices for CTMB notification. It is also essential that involved individual(s) and/or institutions follow their own institutional scientific misconduct procedures in these matters.



PRELIMINARY REPORT OF AUDIT FINDINGS

Public Health Service
National Institutes of Health
National Cancer Institute
Bethesda, Maryland 20892

Complete & Save

Additional Comments:

N/A

UPLOAD THIS REPORT TO THE CLINICAL TRIALS MONITORING BRANCH (CTMB) AT NCI/CTEP INTO THE CTMB-AIS DATABASE WITHIN ONE WORKING DAY OF COMPLETING THE AUDIT .

Any data irregularities identified through quality control procedures or through the audit program that raise any suspicion of intentional misrepresentation of data must be immediately reported to CTMB. The CTMB must be notified immediately by telephone [(240) 276-6545] of any findings suspicious and/or suggestive of intentional misrepresentation of data and/or disregard for regulatory safeguards for any component (regulatory documentation, pharmacy and patient case review) of an audit. Similarly, any data irregularities identified through other quality control procedures suspicious and/ or suggestive of intentional misrepresentation of data must be immediately reported to CTMB. It is the responsibility of the Network Group or NCORP Research Base to immediately notify CTMB when they learn of any significant irregularities or allegations related to scientific misconduct by a staff member or institution participating in their research program. It should be emphasized that the irregularity/misrepresentation of data does not need to be proven, a reasonable level of suspicion suffices for CTMB notification. It is also essential that involved individual(s) and/or institutions follow their own institutional scientific misconduct procedures in these matters.